I
Cardiac clarity
An ECG or EKG, QTc interval assessment, electrolyte levels, vital signs, and cardiac history establish whether known risk factors require exclusion or further evaluation.
Independent information resource
Ibogaine Preparation and Screening: A Checklist
Preparation is not a dosing guide or a wellness ritual. For people considering ibogaine, it is a disciplined process of medical screening, interaction review, psychological assessment, and emergency readiness.
Statement of purpose
Risk management comes before any discussion of treatment.
Ibogaine is an alkaloid associated with Tabernanthe iboga. Interest in ibogaine for opioid use disorder, depression, and other substance use concerns has grown faster than the evidence and regulatory infrastructure. In the United States, it has no FDA-approved therapeutic indication; the FDA’s ibogaine safety information emphasizes serious concerns around cardiac effects and other adverse events.
Medical screening cannot make ibogaine risk-free. It can identify contraindications, establish a baseline, reveal medication interactions, and clarify whether a clinical setting has the medical supervision and emergency protocols needed to respond if a cardiac arrhythmia or other complication occurs.
This resource is intended for people seeking a careful framework for ibogaine preparation and screening. It does not offer detoxification instructions, a therapeutic dose, a flood dose, a booster dose, or permission to self-screen.
Three pillars
The preparation standard is deliberately high.
A credible clinical protocol treats medical history, current substance use, and the practical capacity for medical supervision as connected questions rather than separate checkboxes.
II
Interaction control
A medication review, toxicology screen, tapering schedule, washout period, and assessment of liver function help identify combinations that can increase adverse events.
III
Continuity of care
Psychiatric evaluation, psychological preparation, aftercare, psychotherapy, and integration should be arranged before—not improvised after—an acute experience.
Pillar one
Why medical screening is critical for ibogaine therapy
Medical screening begins with a complete medical history, physical exam, medication and supplement review, recent substance use assessment, and baseline vital signs. Blood pressure, heart rate, prior fainting, family history of sudden death, and known heart disease are material to risk. Current patient criteria considerations are useful only when interpreted by qualified professionals with access to the whole record.
Ibogaine delays ventricular repolarization by blocking hERG potassium channels, which can lengthen the QTc interval. That is why medical screening is not a simple administrative step: prolonged QTc can create vulnerability to torsades de pointes, a dangerous cardiac arrhythmia that may become fatal. The clinical meaning of long QT syndrome helps explain why a person with no known heart diagnosis may still require caution.
Essential cardiac screening and QTc interval assessment
A 12-lead ECG is mandatory in pre-treatment screening, and an EKG should be reviewed for rhythm, conduction changes, and the QTc interval. A baseline QTc interval exceeding 450 milliseconds for biological men or 470 milliseconds for biological women is generally treated as an absolute contraindication. Long QT syndrome, prior cardiac arrhythmia, unexplained syncope, or concerning ECG findings require exclusion criteria or specialist-led evaluation.
For older people or people with cardiac risk factors, a clinical protocol may also use a 24-hour holter monitor, an echocardiogram, or stress echocardiogram. Repeat ECG or EKG measurement after a washout period can matter when medications, acute withdrawal, or electrolyte levels may have altered the baseline QTc interval.
During administration and the acute experience, continuous cardiac telemetry, repeated vital signs, heart rate observation, blood pressure checks, and emergency protocols are central to medical supervision. These safety guidelines address the possibility of torsades de pointes and fatal ventricular cardiac arrhythmia; they do not erase residual risk.
Medical record review
Laboratory testing establishes the metabolic baseline.
Liver and kidney
A complete blood count and metabolic panel should assess liver function, liver enzymes, kidney function, and a renal panel. AST, ALT, bilirubin, hepatitis, liver cirrhosis, or compromised clearance may change exclusion criteria.
Electrolyte stability
Electrolyte levels require specific attention to potassium and magnesium. Protocols commonly seek potassium above 4.0 mEq/L and magnesium above 2.0 mg/dL because low values can sharply raise arrhythmia risk.
Clearance and exposure
Ibogaine is metabolized mainly in the liver through CYP2D6 into noribogaine. CYP2D6 poor metabolizers may have prolonged clearance and elevated ibogaine exposure, increasing cardiovascular vulnerability.
Pillar two
Medication tapering guidelines and contraindicated substances
Medication changes should never be improvised. A prescriber-directed tapering schedule considers each drug’s half-life, indication, withdrawal risk, and interaction profile. Preparation guidance should be individualized, as reflected in these pre-treatment planning considerations, rather than reduced to a universal calendar.
SSRIs and other antidepressants can be relevant because combining serotonergic substances with ibogaine may precipitate serotonin syndrome. Fluoxetine and some antidepressants have a long half-life and may require a four-to-six-week washout period. Other antidepressants, MAO-active substances, and supplements require separate review; serotonin syndrome is a medical emergency, not a manageable side effect.
Methadone, buprenorphine, and Suboxone also require careful planning. Long-acting opioids may be transitioned to short-acting opioids three to six weeks before ibogaine because receptor occupancy, delayed clearance, and acute withdrawal complicate detoxification. A tapering schedule for methadone or buprenorphine must be medically supervised, particularly for opioid use disorder where relapse and overdose risk are significant.
Stimulants, alcohol, unregulated botanical products, and non-prescribed substance use can add uncertainty. A toxicology screen immediately before dosing is used to confirm disclosure and identify contraindications. Guidance from one preparation overview should never replace a clinician’s medication reconciliation and medical supervision.
Metabolic testing and CYP2D6 enzyme profiling
CYP2D6 status may be part of a more conservative clinical protocol because it influences conversion of ibogaine to noribogaine and the duration of exposure. Noribogaine is long-acting, so decisions about therapeutic dose, observation, and discharge planning cannot rely on the acute experience alone. Liver function and kidney function help clinicians understand whether metabolic clearance could be impaired.
A comprehensive metabolic panel, complete blood count, liver enzymes, renal panel, potassium, magnesium, and toxicology screen are practical parts of medical screening. Repeating electrolyte levels is prudent if vomiting, diarrhea, dehydration, poor intake, or acute withdrawal could have changed potassium or magnesium after the initial baseline.
Pillar three
Psychiatric screening and mental health contraindications
A psychiatric evaluation should review diagnosis, prior episodes, current symptoms, medication use, self-harm risk, trauma history, sleep, support, and capacity for informed consent. Ibogaine is not a substitute for stabilization when mental health symptoms are severe or unmanaged.
Schizophrenia, schizoaffective disorder, active psychosis, and type 1 bipolar disorder are strict exclusion criteria because psychedelic therapy can trigger prolonged psychotic episodes or destabilization. Severe active dissociation, borderline personality disorder with active self-harm, and severe unmanaged trauma require specialized psychological stabilization before any psychedelic therapy is considered.
Psychological preparation means developing a clear intention, rehearsing grounding techniques, identifying support, and arranging psychotherapy for integration. It is not a promise that an intense experience will resolve depression, trauma, or substance use. A review of questions to consider before ibogaine can support informed discussion, but does not determine medical eligibility.
Physical preparation and nutritional optimization
Physical preparation includes following clinician-specific instructions about hydration, meals, travel, sleep, and withdrawal management. Hydration does not correct unsafe electrolyte levels, and supplements are not a substitute for laboratory testing. Potassium and magnesium should be measured, interpreted, and corrected only under appropriate medical supervision.
People sometimes encounter supplement lists online, including supplement information associated with ibogaine. Because supplements may affect metabolism, blood pressure, the central nervous system, or cardiac rhythm, every product belongs in the medication review and may be a contraindication until evaluated.
Psychological readiness and intention setting
A realistic intention can orient psychological preparation: recovery support, insight, or a commitment to follow-up care. It should not be framed as a guarantee of detoxification, neuroplasticity, or relief from opioid use disorder. The National Institute on Drug Abuse treatment guidance underscores that ongoing evidence-based care remains important for substance use conditions.
Frameworked methodology
Step-by-step ibogaine preparation checklist
- Disclose the full medical history. Include heart disease, fainting, long QT syndrome, seizures, liver function concerns, kidney function concerns, pregnancy-related considerations, psychiatric history, and prior adverse events.
- Complete medical screening. Obtain a physical exam, vital signs, blood pressure, heart rate, ECG or EKG, baseline QTc interval, complete blood count, metabolic panel, liver enzymes, renal panel, potassium, magnesium, and toxicology screen.
- Resolve cardiac questions. Repeat ECG testing when needed and consider holter monitor or echocardiogram review for relevant age, symptoms, medical history, or risk factors.
- Review every medication and supplement. Identify SSRIs, other antidepressants, methadone, buprenorphine, Suboxone, stimulants, alcohol, and products requiring a washout period or tapering schedule.
- Confirm psychiatric evaluation. Screen for psychosis, bipolar disorder, depression severity, trauma, self-harm risk, substance use patterns, and the exclusion criteria relevant to psychedelic therapy.
- Verify the clinical setting. Ask whether continuous telemetry, ECG capability, emergency protocols, trained medical supervision, and transfer planning are in place for a therapeutic dose or flood dose.
- Arrange aftercare first. Identify psychotherapy, recovery support, integration appointments, and practical support for the period after the acute experience.
Continuity beyond screening
Post-treatment aftercare and integration planning
Aftercare begins before any ibogaine exposure. Noribogaine can persist beyond the acute phase, and a person’s physical, emotional, and substance use risks may change as withdrawal, sleep disruption, mood shifts, or cravings emerge. Integration gives that period structure through psychotherapy, recovery support, medical follow-up, and harm reduction planning.
For opioid use disorder, detoxification without continuing care can leave a person vulnerable to relapse and overdose because tolerance may be reduced. A plan should account for medication options, overdose prevention, social supports, and a return to medical care if vital signs, blood pressure, heart rate, mood, or substance use become concerning.
Some organizations describe their intake and follow-up process, such as an example of a staged process; the important question is whether aftercare and integration are specific, accessible, and matched to the person’s psychiatric evaluation and medical history.
Prelimigaine Screening is a newly launched independent information company. Our approach to clear, evidence-first information explains why we separate educational frameworks from clinical claims, and the scope of our information resources is designed to help readers prepare questions for qualified professionals.
Questions for informed discussion
Frequently asked questions about ibogaine screening
Why is cardiac screening mandatory before taking ibogaine?
Ibogaine can prolong the QTc interval, which may create risk of torsades de pointes and a life-threatening cardiac arrhythmia. An ECG or EKG, baseline QTc interval, medication review, potassium and magnesium testing, and medical supervision are needed to identify risk—not to guarantee safety. Continuous telemetry and emergency protocols matter during the acute period.
Which medications and substances must be tapered prior to ibogaine treatment?
Potential interactions require individualized review. SSRIs, other antidepressants, methadone, buprenorphine, Suboxone, stimulants, alcohol, botanical products, and other substance use may require a tapering schedule, transition, or washout period. Fluoxetine can require a four-to-six-week washout period because of its long half-life. Never stop medication without clinician direction.
What blood tests are required during the ibogaine medical screening process?
Medical screening commonly includes a complete blood count, comprehensive metabolic panel, liver function testing, liver enzymes, kidney function testing, renal panel, electrolyte levels including potassium and magnesium, and a toxicology screen. CYP2D6 profiling may also be considered because CYP2D6 affects conversion of ibogaine to noribogaine and clearance.
How long does the ibogaine preparation and tapering phase take?
There is no universal timeline. The preparation and tapering phase depends on medical history, current medication, half-life, substance use, acute withdrawal risk, and the need to stabilize electrolyte levels or repeat an ECG. Antidepressants and long-acting opioids such as methadone and buprenorphine may require weeks of medically supervised planning before a person can be reassessed.
Who is medically excluded from undergoing ibogaine therapy?
Exclusion criteria can include a prolonged QTc interval, long QT syndrome, significant cardiac disease, unsafe potassium or magnesium values, compromised liver function or kidney function, interacting medications, and certain pregnancy-related concerns. Active psychosis, schizophrenia, schizoaffective disorder, and type 1 bipolar disorder are also serious psychiatric contraindications. A psychiatric evaluation and clinical protocol determine individual eligibility.
A final standard
Preparation should produce better questions—not false confidence.
Use this checklist to organize a conversation about medical screening, ECG results, QTc interval, medication tapering, emergency protocols, psychological preparation, and aftercare with appropriately qualified professionals.
Review the screening checklist